Compare INFY & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFY | ARGX |
|---|---|---|
| Founded | 1981 | 2008 |
| Country | India | Netherlands |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.5B | 42.9B |
| IPO Year | 1999 | 2017 |
| Metric | INFY | ARGX |
|---|---|---|
| Price | $12.77 | $785.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 19 |
| Target Price | $14.60 | ★ $1,008.56 |
| AVG Volume (30 Days) | ★ 15.7M | 268.8K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.87 | $44.39 |
| Revenue Next Year | $6.67 | $20.84 |
| P/E Ratio | ★ $19.11 | $33.69 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.16 | $510.06 |
| 52 Week High | $30.00 | $934.62 |
| Indicator | INFY | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 49.52 |
| Support Level | $12.65 | $758.42 |
| Resistance Level | $14.57 | $855.57 |
| Average True Range (ATR) | 0.36 | 21.23 |
| MACD | -0.01 | -2.81 |
| Stochastic Oscillator | 28.95 | 33.88 |
Infosys is an IT services provider based in Bengaluru, India, with offices in more than 50 countries. The company leverages its offshore outsourcing model to serve clients across different industries, such as financial services and manufacturing. Infosys' IT services offerings include consulting, digital transformation, and business process outsourcing.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.